There have been no clinical responses in patients with mantle cell lymphoma thus far ... resulted in NF-κB inactivation, mediating Bcl-2 and Bcl-XL downregulation, along with c-Myc degradation.

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine ...

AstraZeneca's BTK inhibitor Calquence has become the first drug in the class to be approved by the US FDA as a treatment for adult patients with previously untreated mantle cell lymphoma (MCL ...

The Food and Drug Administration (FDA) has granted traditional approval to Calquence (acalabrutinib) with bendamustine and Rituxan (rituximab) for adults with previously untreated mantle cell lymphoma ...

2 "New treatment options have long been needed in the first-line treatment of mantle cell lymphoma in the US. Patients with this rare and often aggressive cancer can experience severe symptoms by the ...

Table 2. Distinction ... pattern Follicular lymphoma Table 4. Distinction between atypical lymphoid proliferations composed predominantly of B cells and B-cell lymphomas.

FDA Approves New Drug Combination for Mantle Cell LymphomaThe FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL).

including a BTK inhibitor and BCL-2 inhibitor and adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor.

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...